Dominant Lethal Pathologies in Male Mice Engineered to Contain an X-Linked DUX4 Transgene

Abhijit Dandapat,1,5,7 Darko Bosnakovski,1,2,7,8 Lynn M. Hartweck,1,2 Robert W. Arpke,1,2 Kristen A. Baltgalvis,3 Derek Vang,4 June Baik,1,6 Radbod Darabi,1,6 Rita C.R. Perlingeiro,1,6 F. Kent Hamra,4 Kalpna Gupta,4 Dawn A. Lowe,3 and Michael Kyba1,2,*

1Lillehei Heart Institute, University of Minnesota, 2231 6th Street SE, Minneapolis, MN 55455, USA
2Department of Pediatrics, University of Minnesota, 2231 6th Street SE, Minneapolis, MN 55455, USA
3Program in Physical Medicine and Rehabilitation, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
4Vascular Biology Center, Division of Hematology, Oncology, and Transplantation, Department of Medicine MMC 480, 420 Delaware Street SE, University of Minnesota, Minneapolis, MN 55455, USA
5Department of Pharmacology, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
6Department of Medicine, University of Minnesota, 312 Church Street SE, Minneapolis, MN 55455, USA
7Co-first author
8Present address: University Goce Delčev-Štip, Faculty of Medical Sciences, Krste Misirkov b.b., 2000 Štip, R. Macedonia
*Correspondence: kyba@umn.edu

SUMMARY

Facioscapulohumeral muscular dystrophy (FSHD) is an enigmatic disease associated with epigenetic alterations in the subtelomeric heterochromatin of the D4Z4 macrosatellite repeat. Each repeat unit encodes DUX4, a gene that is normally silent in most tissues. Besides muscular loss, most patients suffer retinal vascular telangiectasias. To generate an animal model, we introduced a doxycycline-inducible transgene encoding DUX4 and 3’ genomic DNA into a euchromatic region of the mouse X chromosome. Without induction, DUX4 RNA was expressed at low levels in many tissues and animals displayed a variety of unexpected dominant leaky phenotypes, including male-specific lethality. Remarkably, rare live-born males expressed DUX4 RNA in the retina and presented a retinal vascular telangiectasia. By using doxycycline to induce DUX4 expression in satellite cells, we observed impaired myogenesis in vitro and in vivo. This mouse model, which shows pathologies due to FSHD-related D4Z4 sequences, is likely to be useful for testing anti-DUX4 therapies in FSHD.

INTRODUCTION

Facioscapulohumeral muscular dystrophy (FSHD) is a common degenerative myopathy caused by illicit recombination within D4Z4, a subtelomeric macrosatellite repeat on chromosome 4 (van Deutekom et al., 1993; Wijmenga et al., 1992). Array contractions cause chromatin changes (de Gref et al., 2009; Gabelini et al., 2002; van Overveld et al., 2003; Zeng et al., 2009) but cause disease only on a specific allele of chromosome 4, termed 4qA161 (Lemmers et al., 2004, 2007). FSHD nonpermissive alleles, and related D4Z4 repeats on chromosome 10 (Bakker et al., 1995; Deidda et al., 1996), lack an ATTAAA polyadenylation sequence downstream of the terminal repeat (Dixit et al., 2007; Lemmers et al., 2010). These data suggest that repeat contractions result in an mRNA transcript produced from D4Z4, which must be polyadenylated to cause disease.

The D4Z4 transcript bears an open reading frame encoding a double homeodomain protein named DUX4 (Gabriëls et al., 1999), and this protein is specifically expressed, albeit extremely weakly, in FSHD (Dixit et al., 2007; Snider et al., 2010). Expression of DUX4 at very low levels interferes with myogenesis and sensitizes cells to oxidative stress (Bosnakovski et al., 2008a). These low-level effects are intriguing as defects in myogenic gene expression (Celegato et al., 2006; Winokur et al., 2003a) and sensitivity to oxidative stress (Turki et al., 2012; Winokur et al., 2003b) have been detected in FSHD muscle and primary cell cultures. High levels of DUX4 expression cause rapid cell death in vitro (Bosnakovski et al., 2008a; Kowaljow et al., 2007).

In addition to muscle wasting, most individuals afflicted with FSHD have subclinical retinal vascular pathologies involving vascular tortuosity, microaneurysms, occlusions, and occasionally small exudates (Fitzsimons et al., 1987; Padberg et al., 1995). A transgenic mouse has recently been described that carries an insertion of tandem arrays of a 2.5-unit FSHD allele. Although transcription could be detected in several tissues, and very rare DUX4+ nuclei were detected in cultured cells from this animal (Krom et al., 2013), the animal was normal except for an eye keratitis that developed with age. With the aim of studying the effect of DUX4 expression in vivo, we generated mice with a doxycycline (dox)-inducible DUX4 transgene upstream of hypoxanthine phosphor-ribosyl transferase (HPRT) on the X chromosome. Unexpectedly, in the absence of dox, these animals display a variety of pathologies. We characterize these pathologies and use this model to investigate effects of D4Z4/DUX4 expression on myogenic progenitor cell activity.
RESULTS

To generate a dox-inducible, DUX4-expressing mouse, we used inducible cassette exchange recombination (Bosnakovski et al., 2008a; Iacovino et al., 2011) to insert a genomic DNA fragment encoding the DUX4 open reading frame and 3’ sequences from the terminal D4Z4 repeat up to the EcoR I site into a euchromatic site on the X chromosome. This site, upstream of a functional HPRT gene, was chosen for its ability to give reliable transgene expression (Bronson et al., 1996; Cvetkovic et al., 2000; Portales-Casamar et al., 2010; Touw et al., 2007). The integration places this genomic DNA into a dox-inducible locus regulated by a second generation, tight, tet-response element (Agha-Mohammadi et al., 2004). The reverse tetracycline transactivator for the Tet-On system is expressed ubiquitously from Rosa26 (Hochedlinger et al., 2005). The integration vector provides an SV40 poly A signal downstream of the inserted DNA. We named this transgene iDUX4(2.7), because DUX4 is on a 2.7 kb genomic fragment (Figure 1A).

The iDUX4(2.7) Transgene Is Male-Specific Dominant Lethal

Blastocyst injection generated chimeric males with poor transmission of the transgene: only two F1 progeny were obtained after 1 year of mating chimeras to C57BL/6 females. These carrier females displayed a striped mosaic scaly skin, mild alopecia phenotype. They transmitted the transgene to female progeny, but most litters lacked male carriers (Figure 1B), demonstrating that the DUX4(2.7) transgene behaved as a male-specific dominant embryonic lethal. Evaluation of embryonic litters at embryonic day 14.5 (E14.5) revealed male carrier fetuses with various degrees of developmental delay (Figure 1C). Rarely, carrier males survived to birth, and these animals were runted, displayed the skin phenotype homogeneously, and invariably died before 2 months of age. Notably, when carrier males survived to term, they were usually of similar size to littermate controls at birth. The runting and the skin phenotypes usually became apparent within a few days but were sometimes not initiated until the second week (Figure 1D), and by 6 weeks, iDUX4(2.7) males were significantly underweight (Figure 1E). On histological examination, the skin was found to have excessive numbers of cells, in both the epidermis and dermis (Figures 1F and 1G), features that may explain the flaky scaly skin, and alopecia. We evaluated various tissues from affected males for leaky expression of the transgene (Figure 1H). Unexpectedly, expression in skin, as in most other tissues, was very low and inconsistently detected at 38 cycles of RT-PCR. Nor did we detect the DUX4 protein in any tissues in the absence of dox. This situation is very reminiscent of patients with FSHD, in which spliced RNA transcripts from the terminal D4Z4 element can be detected by RT-PCR in most samples but protein is exceedingly difficult to detect.

However, DUX4 mRNA was consistently detected in testis, retina, and brain. DUX4 has been detected in normal human testis (Snider et al., 2010), and FSHD patients present retinal vascular defects; therefore, we evaluated these tissues in greater detail. Compared to sibling controls, testes of 42-day-old iDUX4(2.7) males displayed a marked defect in gametogenesis. Seminiferous tubule cross sections showed almost complete loss of spermatocytes during late prophase in most tubules. This resulted in relatively few tubules that contained round haploid spermatids and a lack of elongating spermatids compared to wild-type (WT) siblings (Figures 2A and 2B).

To evaluate retinae, we generated montages of 2 stack laser-scanning confocal microscopy images of retinal whole mounts stained with PECAm antibody. The iDUX4(2.7) males displayed features associated with telangiectasia: excessive branching with looping and twisted retinal vessels, which appear more dilated than control retinae (Figures 2C and 2D). Morphometric analysis of these images revealed a dramatic increase in vessel branching (nodes), as well as significant increases in vessel length and overall density of vessels in iDUX4(2.7) males compared to controls (Figures 2E–2G), suggestive of increased neovascularization.

iDUX4(2.7) Males Have Proportionally Weaker Muscles but Show No Evidence of Muscular Dystrophy prior to 6 Weeks of Age

Muscles of the iDUX4(2.7) males were smaller than those of their matched sibling controls and fibers were fewer and smaller; however, muscles did not become overtly dystrophic within the short lifespan of these mice (Figure 3A). Grip-strength measurements revealed that the iDUX4(2.7) males were much weaker than sibling controls, but strength was proportional to body size (Figure 3B). We measured the force-generation capacity of isolated extensor digitorum longus (EDL) and soleus muscles. Both muscles produced much lower absolute force; however, when normalized to muscle cross-sectional area, the specific force-generating capacity was not significantly different from WT (Figures 3C and 3D). Soleus muscle fiber type distribution, based on myosin heavy chain isoform expression (types 1, 2a, and 2x), was not different between iDUX4(2.7) and wild-type mice (Figure 3E).

Demethylation of DUX4 in Myogenic and FAP Progenitors from Muscle

To determine whether the integrated transgene more resembled an FSHD-associated or a WT allele, we evaluated methylation of the transgene in rare live-born iDUX4(2.7) males by bisulfite sequencing. We initially evaluated testis and hind limb muscle, tissues with visualizable versus barely detectable DUX4 mRNA. Remarkably, in both tissues, the transgene was completely demethylated (Figure 4A). We then initiated cultures of total muscle progenitor cell types (Figures 4A and S1).

Biased X Inactivation in Females

We then investigated methylation in females, using peripheral blood samples of female iDUX4(2.7) heterozygous breeders. In stark contrast to males, sequences from females indicated that the gene could be in one of two states: either similar to that seen in males or heavily methylated. This is consistent with X inactivation, which, when it occurred on the
A

Terminal D4Z4 repeat

DUX4 ORF

iDUX4(2.7) transgene

B

iDUX4(2.7) N1 pups

Number of Offspring

Expected P<0.001

Female  Male

C

X^D4^/Y  X^D4^/X^wt^  X^D4^/Y  X^wt^/Y

Female  Male

D

WT Control  iDUX4(2.7)

E

Body weight (g)

Control  iDUX4(2.7)

F

Epidermal thickness (μm)

Control  iDUX4(2.7)

G

Dermal density (molecules/μm^2)

Control  iDUX4(2.7)

H

Control  iDUX4(2.7) Male

Limb, Retina, Diaphragm, Skin, Brain, Thymus, Liver, Spleen, Intestine

Dux4, -RT, Gapdh

(legend on next page)
DUX4-bearing X, would result in high levels of methylation. Because X inactivation is random, an equal proportion of the two states is expected. Remarkably, the methylated sequences greatly outnumbered the demethylated sequences in females (Figure 4B). This X inactivation bias strongly suggests that there is selection against cells that inactivate the WT X, leading female heterozygotes to be composed mainly of cells in which the DUX4-bearing X was inactivated.

Expression of DUX4 in Muscle-Derived Progenitors
In contrast to the difficulty of detecting DUX4 transcript in primary muscle tissue, the DUX4 transcript was detectable at low levels in both myoblasts and FAPs (Figure 4C). Notably, in iDUX4(2.7) cultures, the FAP population predominated prior to FACS and isolated iDUX4(2.7) myoblasts had a clear growth disadvantage compared to their WT controls, whereas iDUX4(2.7) FAPs showed no growth disadvantage (Figure 4D). We next sought to detect the DUX4 protein in isolated myoblasts and FAPs. We found no detectable protein expression in FAPs (not shown); however, myoblast cultures consistently showed scattered cells with nuclear DUX4 protein (Figure 4E), similar to what was seen with the D4Z4 mouse (Krom et al., 2013). The protein could also be...
detected, and at greater frequency, in nuclei from differentiated myotubes, often in groups of adjacent nuclei. Quantification revealed that about 5% of myonuclei from differentiated cultures stained DUX4+, whereas in the myoblast cultures, DUX4 protein was present in about 1.5% of nuclei (Figure 4F). This result is not necessarily suggestive of greater expression in differentiated cultures: myotubes are syncitia, therefore active DUX4 transcription in one nucleus can lead to uptake and positive staining of nuclear proteins in nearby myonuclei (Block et al., 2013; Tas-sin et al., 2013), so at the same frequency of expression, myotubes are predicted to have greater numbers of positive nuclei than myoblasts. Indeed, a careful comparison of two independent myoblast and myotube cultures revealed very similar levels of expression at the RNA level before versus after differentiation (Figure 4G), although it is important to point out that these results are nonquantitative. The lack of detectable protein in most nuclei by immunostaining, as well as the lack of detectable protein in FAPs, may indicate the sensitivity of the assay is limiting. Indeed, between laboratories, the immunohistochemical method has produced widely varying estimates of frequencies of nuclei positive for DUX4 in FSHD (and control) myoblasts (Jones et al., 2012; Snider et al., 2010).
Induced DUX4 Expression Is Selectively Deleterious to Myogenic Progenitors

The studies described above were undertaken in the absence of dox; therefore, phenotypes are due to extremely low-level, leaky expression. To evaluate the utility of dox-mediated DUX4 expression, we tested whether the inducible locus was functional by treating myoblast and FAP cultures with a high dose of dox (500 ng/ml) for 24 hr. This confirmed that the inducible system was indeed working as expected: DUX4 protein was expressed in response to dox (Figure 5A). We then subjected ex vivo cultures of myoblasts and FAPs to various lower concentrations of dox. In both myoblasts and FAPs, expression of DUX4 was deleterious; however, growth inhibition was more severe in myoblasts (Figures 5B and 5C).

Low, nontoxic levels of DUX4 expression were shown to interfere with the differentiation of C2C12 myoblasts (Bosnakovski et al., 2008a). To determine DUX4 effects on primary cells, we induced differentiation of myoblasts (into myotubes) and FAPs (into adipocytes) in the presence of low levels of dox (50 ng/ml). Myotube formation was clearly impaired by DUX4 expression, whereas adipocyte differentiation was unaffected (Figure 5D).

DUX4 Impairs Myogenic Regeneration In Vivo

To test the effect of DUX4 expression during myogenic regeneration in vivo, we transplanted 1,800 FACS-isolated satellite cells from hind limb muscle of iDUX4(2.7) mice into preinjured, irradiated tibialis anterior muscles of NSG-mdx4Cv mice (Arpke et al., 2013). The recipients lack dystrophin; thus, the amount of donor muscle tissue produced by the transplanted cells can be quantified by immunostaining for dystrophin. We found that treatment of mice with 5 mg/kg doxycycline severely impaired the ability of donor satellite cells to produce new muscle (Figures 6A and 6B). This indicates that DUX4 expression is deleterious to muscle regeneration in vivo.

DISCUSSION

FSHD is one of the most enigmatic of the muscular dystrophies, and despite many efforts, there is no genetic model that displays any phenotype for this disease. In humans, reduction in repeat number (or second-site mutation in rare noncontraction cases; e.g., FSHD2; Lemmers et al., 2012), clearly leads to an epigenetic number (or second-site mutation in rare noncontraction cases; any phenotype for this disease. In humans, reduction in repeat

Although a recently described mouse bearing randomly integrated tandem D4Z4 repeats from an FSHD allele showed some expression of D4Z4 transcript (Krom et al., 2013), this animal did not present profound pathologies. With the recognition that DUX4 has potent myogenesis-relevant phenotypes even at very low levels of expression in C2C12 cells (Bosnakovski et al., 2008a), we sought to generate an animal model based on low-level regulated and systemic expression of DUX4. Systemic expression is relevant because D4Z4 misexpression in FSHD has not been shown to be restricted to myoblasts or muscle fibers. Indeed, the presence of nonmuscle phenotypes such as retinal vascular pathology (Fitzsimons et al., 1987; Gieron et al., 1985; Small, 1968) and sensorineural hearing loss (Brouwer et al., 1991; Lutz et al., 2013) in FSHD patients, the syndrome of phenotypes associated with very severe infantile FSHD cases with extremely short D4Z4 arrays (Chen et al., 2013), together with the demonstration of epigenetic changes also in the blood cells of FSHD patients (Hartweck et al., 2013; van Overveld et al., 2003), suggests that misexpression is not restricted to muscle and might be a global feature. Remarkably, in our allele, we found that low-level leaky and variable expression led to several severe phenotypes, making the iDUX4(2.7) mouse an animal model in which FSHD allele-specific DNA has been integrated into the genome and caused a serious pathology.

This pathology is dominant, like FSHD, but dramatically more potent, resulting in male-specific lethality. In humans, the D4Z4 repeats are embedded in subtelomeric heterochromatin and subject to repeat-induced silencing, whereas in this mouse model, the transgene has been inserted into euchromatin and is present in only a single copy. Thus, D4Z4 has lost both the opportunity for repeat-induced silencing as well as its normal heterochromatic genomic environment, both changes that would be predicted to render the transgene more potent than 4q35-linked FSHD alleles (Figure 7). This may explain why the DUX4 transgene has a much stronger dominant-lethal phenotype in this mouse model than in human patients with FSHD. It may also explain the presence of phenotypes in unexpected tissues, for example, skin; however, vector-specific sequences may also contribute to tissue-specific aspects of the leakiness, for example, the minimal promoter might be leaky in skin cells, whereas the endogenous human D4Z4 might not show skin expression. For obvious reasons, outside of muscle biopsies, a careful analysis of tissues in which DUX4 expression can be

Figure 4. Methylation and DUX4 Expression in Primary Cells

(A) Methylation of the iDUX4(2.7) transgene in various tissues and primary muscle cells. Bisulfite-treated DNA was amplified by PCR, cloned, and sequenced. Blue boxes indicate unmethylated cytosines of CpG dinucleotides, and red boxes indicate methylated cytosines along the PCR product.
(B) Methylation of the transgene in male and female peripheral blood. One male aged 6 weeks and three independent females aged 6, 9, and 36 weeks are shown. Methylated sequences in females were greatly overrepresented compared to the 1:1 ratio predicted by X inactivation for a heterozygous female (p = 0.9).
(C) RT-PCR detection of the DUX4 transcript in proliferating myoblasts and FAPs.
(D) Growth rate of iDUX4(2.7) myoblasts and FAPs compared to cells from WT littermate controls. Myoblasts displayed a significant growth disadvantage. No difference was seen in FAP growth rate. One experiment of three similar replicates is shown.
(E) Immunofluorescent detection of DUX4 protein in myoblasts and myotubes. Sections are also stained with DAPI (blue) and antibody to myosin heavy chain (MHC) (in green).
(F) Quantification of DUX4+ nuclei, expressed as average percentage and SD of total per microscopic field, over 19 separate fields. One of three similar replicates is shown.
(G) Comparison of levels of DUX4 expression by RT-PCR in myoblasts versus myotubes. See also Figure S1.
**Figure 5. Effects of Induced DUX4 Expression**

(A) Western blot for DUX4 expression in proliferating myoblasts and FAPs exposed to a high dose (500 ng/ml) of dox. One representative blot of three independent experiments is shown.

(B) Dox dose-response growth curves for myoblasts (left) and FAPs (right) exposed to very low doses of dox to induce DUX4 expression. Myoblasts displayed a more severe growth inhibition and greater sensitivity to dox.

(C) Cellular morphology of proliferating myoblast (left) and FAP (right) cultures exposed to a high dose (500 ng/ml) of dox. Myotubes (left) were stained for myosin heavy chain; adipocytes (right) were stained with Oil Red O. Note that low-dose induction of DUX4 inhibits myogenic, but not adipogenic, differentiation.
detected in humans has never been reported. With regard to pathologies in testes, this was somewhat surprising as DUX4 has been reported in human testes (Snider et al., 2010). The closest mouse homolog, Dux, was not reported expressed in testes (Clapp et al., 2007); however, a different double homeobox protein, Duxbl, which lacks the C-terminal sequence conserved between DUX4 and mouse Dux (Leidenroth and Hewitt, 2010) important for toxicity (Bosnakovski et al., 2008b), is expressed in testes (Wu et al., 2010). The presence of testis pathology in iDUX4(2.7) mice suggests that, if DUX4 has a specific function in testes, then this is probably a human-specific activity.

It is notable that the retinae of the iDUX4(2.7) animals demonstrate pathological retinal vascular changes like those seen in FSHD patients. It is not yet understood how the D4Z4 contraction leads to these changes in humans; however, it has been proposed that the muscle pathology and the retinal pathology might both be attributed to an endothelial defect (Osborne et al., 2007). The iDUX4(2.7) mice also resemble FSHD patients in terms of DUX4 expression at the RNA and protein level: a spliced mRNA encoding DUX4 can be detected at very low levels in many tissues, but the DUX4 protein itself cannot or is expressed in so few cells as to be difficult to distinguish from background in immunostaining experiments. Within the short lifespan of the rare live-born affected males, a muscular dystrophy does not develop. Whether or not muscular dystrophy (MD) would develop if the animals were to survive beyond 4–6 weeks, the absence of dystrophy is consistent with the lack of muscle pathology in young FSHD patients. The literature is inconsistent on fiber type changes in FSHD (Lin and Nonaka, 1991; Olsen et al., 2005), but neither do the mice show any signs of fiber type switching. Unlike Duchenne MD, in which pathological cycles of damage and regeneration are present from birth, FSHD muscles appear histologically normal prior to onset of the disease. The female mice do survive, but neither did they show signs of muscular dystrophy. However, in heterozygous carrier females, the DUX4 transgene appears to be predominantly on the inactive X chromosome, as it is heavily methylated. As X inactivation is random, this is best explained by positive selection for cells that silence the DUX4-bearing X chromosome.

To evaluate more directly the effect of DUX4 on primary muscle progenitors, we studied myogenic and fibroadipogenic progenitors from iDUX4(2.7) males. DUX4 mRNA was indeed expressed at low levels in both myoblasts and FAPs and was associated with a reduction in proliferative potential, more significantly to myoblasts. Doxycycline induction at high doses was clearly inhibitory to both myoblasts and FAPs, whereas low levels inhibited differentiation of myoblasts into multinucleated myotubes, but not of FAPs into adipocytes. The DUX4 effects on primary muscle progenitors raise the question of whether a defect in regeneration contributes to muscle pathology in FSHD. Accordingly, when iDUX4(2.7) satellite cells were transplanted and recipients treated with a relatively low dose of doxycycline, their ability to generate new muscle tissue was severely impaired. The data do not formally differentiate between effects on progenitors versus newly formed myofibers—certainly when very high levels of DUX4 were delivered directly to mouse muscles tissues by adenov-associated virus, there was extensive degeneration (Wallace et al., 2011). However, the data are consistent with the notion that DUX4 could impair muscle regeneration in FSHD. Most importantly, they represent a quantifiable assay that could be used to study the activity of pharmacological inhibitors of DUX4 in vivo. This is an animal model in which FSHD allele-specific DNA has been integrated into the genome and has generated a pathological phenotype. It clearly demonstrates that even low-level expression from the terminal D4Z4 repeat is highly deleterious; is consistent with a model for FSHD in which muscle wasting is a consequence, at least in part, of impaired regeneration; and presents opportunities for testing activity of anti-DUX4 therapeutics in vivo.

**EXPERIMENTAL PROCEDURES**

**Cloning of Targeting Construct and Generation of iDUX4(2.7) Mice**

The genomic DNA encoding DUX4 from the terminal repeat together with downstream sequence (2.7 kb total) was obtained from pCneo-DUX4 (Gabriëls et al., 1999) and subcloned into XhoI/NotI cloning sites of p2Lox, generating p2lox-DUX4(2.7). iDUX4(2.7)-inducible mouse embryonic stem cell lines, brieﬂ et al., 1999) and subcloned into XhoI/NotI cloning sites of p2Lox, generating p2lox-DUX4(2.7). iDUX4(2.7)-inducible mouse embryonic stem cell lines, 1492 Cell Reports 8, 1484–1496, September 11, 2014 ©2014 The Authors
Figure 7. The iDUX4(2.7) Allele versus Human D4Z4 Alleles

D4Z4 is indicated by a triangle. Methylation state is indicated at six representative sites for each array, with a red ball indicating methylation and an open circle indicating lack of methylation. In humans, when D4Z4 is present in a large tandem array within subtelomeric heterochromatin at 4q, a repeat-induced silencing mechanism leads to heterochromatinization of the array (indicated by compaction of the triangles and their respective methylation marks) and hypermethylation of DNA (indicated by red circles), which effectually silences the locus. When the array number is reduced in an FSHD allele, a loss of repeat-induced silencing leads to an opening up of chromatin (more space between the triangles) and relative demethylation, leading to some transcription of DUX4. In the iDUX4(2.7) mouse, the single copy (which is not subject to repeat-induced silencing) and location within euchromatin results in even greater opening, a complete absence of methylation, and greater transcription in additional tissues, leading to a more severe, lethal, phenotype.

Isolation and Differentiation of Myoblasts and FAPs from Muscle

Preparation of muscle samples was performed as described (Arpke et al., 2013). We then plated 10^6 total mononuclear cells in a T25 flask in F-10/Ham’s (HyClone) medium containing 20% fetal bovine serum (HyClone), 50 ng/ml human basic fibroblast growth factor (Peprotech), 1% penicillin/streptomycin (Gibco), and 1% Glutamax (Gibco) and cultured at 37°C. After 5 days, primary cells were dissociated with 0.05% trypsin (Invitrogen) and resuspended in FACS staining medium. To isolate myoblast and FAP fractions, cells were stained with PDGFRα conjugated with phycoerythrin (e-Biosciences; clone: AP5) and α7 integrin APC. Cells were sorted into a PDGFRα single-positive (FAP fraction) and an α7 integrin single-positive (myoblast) fraction and recultured in the same medium. Myoblasts were differentiated in 20% knockout serum replacer (Invitrogen) as described in Block et al. (2013). FAPs were differentiated in dexamethasone (STEMCELL Technologies) as described in Lemos et al. (2012). To detect DUX4 by western blot or by immunostaining in primary myoblasts and myotubes, ES-S DUX4 antibody (Abcam) was used as described (Geng et al., 2011). Myosin heavy chain staining used the MF20 antibody (Developmental Studies Hybridoma Bank).

Methylation Analysis

Bisulfite sequencing was generally performed as described in Hartweck et al. (2013). Tissues from six male mice at 6 weeks of age and three females aged 6, 9, and 36 weeks were analyzed. DNA was extracted using the PureLink Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was converted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in Genomic DNA Mini Kit (Invitrogen).
were grafted out using anti-CD31 (Bioscience; clone 390) and rat anti-CD45 (Bioscience; clone RA3-6B2) antibodies conjugated to phycoerythrin-Cy7. Finally, satellite cells were sorted by being double positive for CD106 (Bioscience; biotinylated primary VCAM-1 antibody; clone 429; followed by streptavidin secondary antibody conjugated to phycoerythrin) and α7-integrin conjugated with allophycocyanin (AbLab; clone R2F2).

Transplantation was according to Arpke et al. (2013). Briefly, 2 days prior to transplantation of cells, 4-month-old NSG-mdx4Cv mice were anesthetized with ketamine and xylazine and both hind limbs were subjected to a 1,200 cGy dose of irradiation using an X-RAD 320 Biological Irradiator (Precision X-Ray). On the day of transplantation, 1,800 sorted satellite cells were resuspended in 1.2% BaCl2 (RICCA Chemical Company) and injected into tibialis anterior (TA) muscles of NSG-mdx4Cv mice. Every day posttransplantation, we injected mice with PBS or doxycycline at 1 mg/kg or 5 mg/kg. Four weeks after transplantation, six TAs of each group were harvested, sectioned, and immunostained with a mouse monoclonal antibody to laminin (Sigma-Aldrich) and rabbit polyclonal antibody to dystrophin (Abcam) antibodies followed by goat anti-mouse immunoglobulin G (IgG) conjugated with Alexa 488 and goat anti-rabbit IgG conjugated with Alexa Fluor 555 (Life Science Technologies). Images were acquired on a Zeiss Axio Imager M1 Upright microscope with AxioCam HRc camera, and the number of donor-derived fibers (dystrophin+) was determined.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and one figure and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.07.056.

AUTHOR CONTRIBUTIONS

D.B. derived the iDUX4(2.7) mouse and performed initial characterization and assays for DUX4 expression with assistance from J.B. Studies of DUX4 expression and effects on differentiation of myoblasts and FAPs were performed by A.D. L.M.H. performed methylation studies. Transplantation assays were performed by A.D. and R.W.A. with assistance from R.D. K.A.B. and D.A.L. performed muscle force and fiber assays. D.V. and K.G. performed morphometric analyses of retina. F.K.H. performed analysis of testes. M.K., A.D., D.B., L.M.H., K.G., F.K.H., D.A.L., and R.C.R.P. wrote the manuscript.

ACKNOWLEDGMENTS

This project was primarily supported by grants from the NIH (R01 AR055685), the Dr. Bob and Jean Smith Foundation, and the Friends of FSH Research to M.K. and the Muscular Dystrophy Centre Core Laboratory P30 AR0507220. D.B. was supported by a Muscular Dystrophy Association Development Grant (MDA 4361) and a Marjorie Bronfman Research Fellowship from the FSH Society (FSHS-MGBF-016). R.C.R.P. was supported by NIH grants T32-AR055299 and U01 HL100407. K.A.B. was supported by NIH grant T32-AR07512 and D.A.L. by K02-AG036827. K.G. and D.V. were supported by NIH grants R01 HL88802 and R01 HL103773. F.K.H. was supported by NIH grant R01 HD053889.

Received: December 20, 2013
Revised: June 3, 2014
Accepted: July 30, 2014
Published: August 28, 2014

REFERENCES


FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum. Mol. Genet. 2, 2037–2042.


